Clive S. Zent

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson et al. · Haematologica · 2018 · 452 citations · Full text

Medicine, Oncology, Pharmacology +12

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Neil E. Kay, Susan M. Geyer, Timothy G. Call et al. · Blood · 2006 · 293 citations · Full text

Pharmacy, Immunology, Oncology +14

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Michael R. Grever, Omar Abdel‐Wahab, Leslie A. Andritsos et al. · Blood · 2016 · 289 citations · Full text

Medicine, Hematology, Oncology +10

Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Thomas E. Witzig, Stephanie Fink et al. · Journal of Clinical Oncology · 2006 · 249 citations · Full text

Life Sciences, Genetics, Oncology +14

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

Anthony R. Mato, Brian T. Hill, Nicole Lamanna et al. · Annals of Oncology · 2017 · 224 citations · Full text

Medicine, Hematology, Oncology +16